Rise and shine, everyone, another busy day is on the way. And this is an even busier time than usual, thanks to recent intriguing developments. There is only one thing to do, of course, when events threaten to overtake you — fire up the coffee kettle and quaff some cups of stimulation. We are relying on chocolate cherry decadence this morning, for those who track this sort of thing. Meanwhile, here are a few items of interest. Hope your day is interesting and productive. And do drop us a line if you come across anything interesting, such as curious payments to fixers …

President Trump on Friday plans to outline a series of initiatives aimed at curbing drug prices that will be accompanied by proposed rules and a broad request for input from manufacturers, health providers, patients, and others, according to The Wall Street Journal. The administration wants to move some drugs out of Medicare Part B, but the proposals are expected to fall short of earlier ideas backed by Trump, including letting Medicare use its enormous buying power to negotiate drug prices directly with suppliers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy